Medical technology company BD (Becton, Dickinson and Company) (NYSE:BDX) on Tuesday unveiled a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes, in partnership with BioMedomics.
The rapid serology test, which detects exposure to COVID-19 at the point of care in 15 minutes, is completed in four simple steps. The new test, developed and manufactured by BioMedomics, will be available through BD and distributed exclusively by Henry Schein Inc in the US.
According to the partnership, the test does not require special equipment and may be used in a laboratory or at the point of care. The test detects antibodies in the blood that are produced by the body in response to coronavirus infection. These antibodies are typically present in the middle to later stages of COVID-19 infection, but may remain present after exposure, which helps clinicians determine who has been exposed to the coronavirus, even if a person didn't exhibit any symptoms of the COVID-19 disease.
Though the test has not been reviewed by the FDA, it is permitted for distribution and use under the public health emergency guidance issued by FDA on 16 March 2020. BD expects to begin shipping tests in April and supply one million tests over the coming months.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT